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Abstract 
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in 
modeled claims for cost-effectiveness and associated recommendations for pricing by the Institute for Clinical and Economic Review 
(ICER). The principal objection to ICER reports has been that their modeled claims fail the standards of normal science: they are best 
seen as pseudoscience. The purpose of this latest commentary is to consider the recently released ICER report for Additive 
Cardiovascular Disease therapies. This report should not be taken seriously in its claims for cost-effectiveness and pricing in 
cardiovascular disease (CVD). The analytical framework applied by ICER fails to meet the standards of normal science in demarcating 
science from pseudoscience. Irrespective of the value judgements and recommendations of an ICER report, these lack credibility. They 
were never intended to be evaluable and replicable across treatment settings. The claims made are constructed, driven by   assumption, 
and should be put to one side by health system decision makers. In this review the focus is on to the ICER modeled estimates of utility 
scores in CVD, the insistence on utilizing a generic utility algorithm (the EQ-5D-3L) and the consequent quality adjusted life year (QALY) 
estimates. Two issues are raised that will be the subject of future commentaries: the lack of appreciation of fundamental measurement 
and (ii) the importance of the patient voice in benefit claims. Given the importance in the ICER methodology of QALYS, the ad hoc 
nature of the ordinal utilities introduced to the cardiovascular model must raise concerns over the role the ICER evidence report may 
play in health care decision-making. These concerns extend to the claim by ICER that, on ICER’s own affordability threshold for individual 
new molecular entities, the anticipated uptake of these therapies may raise questions of overall affordability. Again, we are dealing 
with an arbitrary construct that may adversely impact patient access.  
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____________________________________________________________________________________________________________ 
Introduction 
The construction of assumption driven model worlds to support 
incremental cost-per-QALY claims for pricing and access 
recommendations is the hallmark of the ICER business model. 
The purpose of this commentary is to review ICER’s latest 
report on additive treatments for cardiovascular disease 
(ATCD), released on 17 October 2019 1. Following previous 
commentaries on ICER evidence reports the focus will be on the 
scientific status of the ICER reference case methodology, with 
particular reference to the claims made for health related 
quality of life (HRQoL).  
 
The evidence report considers separately two additive 
therapies for cardiovascular events for those with stable 
cardiovascular disease: rivaroxaban (Xarelto, Janssen 
Pharmaceuticals) and icosapent ethyl (Vascepa®, Amarin 
Corporation). The report concluded that there was a high 
certainty that rivaroxaban plus aspirin or acetylsalicylic acid  
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(ASA) significantly reduced the risk of cardiovascular death, 
stroke, or MI in patients with stable CVD, with limited evidence 
of any health benefit compared to dual antiplatelet therapy 
(DAPT). In respect of those with established CVD or a high risk 
of cardiovascular events treated with statins, there is a high 
certainty that icosapent ethyl provides a small to substantial 
net health benefit. At the same time, while the products were 
deemed cost effective they were then declared not to meet the 
second ICER hurdle of affordability. This led to ICER issuing an 
Access and Affordability Alert to signal that the health care 
costs associated with the potential uptake of the therapies may 
be difficult for health systems to absorb.  
 
Central to the ICER case for declaring products to be cost-
effective is the construction of a lifetime simulated reference 
case model. The purpose of the ICER ersatz model is to 
construct, by assumption, incremental cost-per-quality 
adjusted life year (QALY) claims for the ICER hypothetical target 
patient population in target disease states. In the case of CVD 
the model, to represent by assumption an unknown clinical 
future, was constructed from a lifetime Markov cohort 
framework. The model compared the addition of rivaroxaban 
to ASA therapy to ASA alone and the addition of icosapent ethyl 
to optimal medical management. The two products were 
modeled separately but within a similar model structure for a 
common hypothetical population. The modeled evaluation 
concluded that, in the base case incremental cost-per-quality 
adjusted life year framework, rivaroxaban versus optimal 
medical management yielded $36,000 per QALY gained while 
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icosapent ethyl versus optimal medical management yielded 
$18,000 per QALY gained. Both are below the lowest ICER 
willingness-to-pay threshold of $50,000 per lifetime QALY. 
 
If a model is constructed by assumptions based upon the 
translation of clinical data, in this case pivotal randomized 
controlled trials, together with assumptions based upon data 
points in the literature or assumptions to be taken at face value 
with little if any literature based justification, then the model 
should be seen as just one of many that can be constructed. As 
the choice of assumptions and the various scenarios presented 
by ICER as adjuncts to its base case model within the reference 
case Markov framework demonstrate, a range of alternative 
cost-per-QALY outcomes are feasible. Add to this the options 
for alternative hypothetical model frameworks (e.g., rule driven 
microsimulation models) and the door opens to a multiverse of 
possible cost-per-QALY hypothetical outcomes. The evidence 
report model can be easily challenged by other imaginary 
constructs given the options open to change assumptions and 
the construction of competing models within the same 
reference case paradigm 2 3 4. A situation where, it might be 
noted, we can then throw in a further option for the modeling 
multiverse: the choice of utility metric to drive the QALY 
estimate. As demonstrated in the health technology 
assessment literature over the past 30 years, ICER-type 
modeled cost-per-QALY cost-effectiveness claims for therapy 
options are entirely discretionary. Indeed, in all too many cases 
we find the products of sponsors of modeled cost-effectiveness 
outcomes confirmed as cost-effective by the model. 
 
The purpose of this commentary is to point out that the ICER 
modeled claims for rivaroxaban and icosapent ethyl, together 
with ICER claims for affordability should not be taken seriously. 
They both fail to meet the standards of normal science. As 
previous commentaries have pointed out, if an ersatz 
incremental cost per QALY model is constructed, then any 
number of similar models can be constructed,5 6 7 8 9. None of 
the claims made for clinical and comparative cost-effectiveness 
are credible, evaluable and replicable. As such, formulary 
committees have no idea whether ICER recommendations are 
right or even if they are wrong, they will never know and they 
were never intended to know.  
 
Embracing the reference case paradigm means that the ICER 
value pronouncements for pricing and access are not, in fact, 
ever meant to meet the standards of normal science. They are 
immune to failure and do nothing to advance our knowledge 
for therapy impacts of the therapies in CVD target patient 
populations 10 11 4.    
 
In order to demonstrate the poverty of the ICER business 
model, a useful distinction is between value judgements and 
value claims. A value judgement, an assessment in terms of 
one’s standards or priorities, characterizes the ICER reference 
case and the construction, by assumption, of an evidence 
framework. ICER is the sole arbiter of the value metric and of 
the criteria that support its claims for pricing and product 
access. A value claim takes a totally different perspective: it 
represents the outcomes that patients, caregivers and 
providers consider appropriate for a target patient population. 
It recognizes that patient reported outcomes instruments, 
including those that cast themselves as capturing quality of life 
(QoL) (or, more narrowly, health related quality of life - HRQoL) 
must be empirically based and subject to evaluation by third 
parties. A value claim must be credible, evaluable and 
replicable. Value claims support an ongoing dialogue that 
captures the contribution and limitations to our present 
knowledge of therapeutic options. Rather than arbitrarily 
imposed criteria for value judgements, where claims are seen 
all too often through the blinkered lens of a selected generic 
metric driven by a simulated model world, value claims 
recognize that knowledge is provisional, not constructed, and 
that the accumulation of knowledge must be evidence based.   
 
ICER and NICE 
It is important to note that ICER has no legislative or regulatory 
mandate for health technology assessment in the US. While it 
has taken upon itself the mandate of sole arbiter for rigorous 
and independent value assessments, its position is significantly 
different from that of the National Institute for Health and Care 
Excellence (NICE) in the UK. While ICER may be seen as a 
simulacrum of NICE (NICE-lite), the facts are that (i) it is not 
operating in a single payer health care system and (ii) it has no 
legislative role to provide guidance on the acceptance of 
technologies as NICE does within the English National Health 
Service (NHS). ICER’s perceived and self-appointed role as an 
arbiter of value judgements for the US health market, 
supported by proclaimed processes of stakeholder 
involvement, clinical benefit assessment, model building and, 
ultimately, voting by an ICER appointed expert panel on the 
merits or otherwise of target therapies, should not obscure the 
fact that the end-result are value judgements that rest on 
constructed evidence. Its clinical assessments and modeled 
claims have no more weight (if any) in decision making than 
other assessment and models that populate the CVD 
technology assessment literature.  
 
NICE takes a reference case approach to establish model 
parameters. In this case, however, rather than an in-house 
model developed by its staff, manufacturers are asked to 
submit their own reference case model. This is typically a 
lifetime incremental cost-per-QALY model with the EQ-5D-3L 
generic HRQoL instrument as the standard utility measure. The 
model is then submitted, if considered appropriate, to an 
independent third party (usually an academic center) for 
appraisal. The appraisers, with experience in the review of 
ersatz lifetime model simulations, can (i) accept the model; (ii) 
modify the model or (iii) create an alternative model. This 
allows transparency in the review process with the final 
decision by NICE. 
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The key point is that with NICE and other countries such as 
Australia, New Zealand and Ireland who have followed NICE’s 
lead in mandating the construction of simulated or modeled 
worlds to support formulary submissions, the requirement has 
legislative and regulatory backing. Value judgements driven by 
the various country models are mandated as key elements in 
formulary decision making. While modeling reference case 
lifetime value judgements might be objected to on grounds of 
scientific merit, there is an acceptance of the approach. While 
this might seem odd, as noted in a recent commentary: The 
playing field is level and all parties know the rules of the ‘game’. 
There are even imaginary world referees, typically in academic 
institutions, who will adjudicate the manufacturer’s imaginary 
submission. They can pronounce whether it is acceptable, 
modifiable or should be replaced by the referees own proposal 
for an imaginary world. NICE, as senior referee, is the judge 12 . 
 
There is no reason why ICER, in its NICE-lite incarnation, should 
assume that value judgements based on constructed evidence 
from simulated worlds should have relevance to health care 
decision making in the US. The US is not a single payer health 
system. There is no legislated or regulatory across-the-board 
requirement for imaginary reference case modeling to support 
value judgements. Certainly, ICER might believe in the sure and 
certain hope that incremental cost-per-QALY lifetime 
simulation models are the ‘state of the art’ in health technology 
assessment, a position taken by professional groups such as the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR); this does not mean that the ICER business 
model standard is appropriate. Indeed, under the Affordable 
Care and Patient Protection Act (2010) it is made clear that the 
Patient Centered Outcomes Research Group (PCORI) must 
exclude discounted cost-per QALY or similar measures as 
threshold values for priority setting in health by the Centers for 
Medicare & Medicaid Services (CMS) 13. While this exclusion 
gives pause to those advocating the use of QALYs in pricing and 
access, the debate overlooks a more substantive concern: the 
ICER business model lacks scientific merit. It is best seen, as 
detailed below, as pseudoscience. As the ICER reference case 
methodology does not meet the standards of normal science 
then any value judgement claims for products should be 
rejected.  
  
Meeting the Standards of Normal Science 
The requirement for testable hypotheses in the evaluation and 
provisional acceptance of claims made for products and devices 
is unexceptional. Since the 17th century it has been accepted that 
if a research agenda is to advance, if there is to be an accretion 
of knowledge, there has to be a process of discovering new facts. 
Indeed, as early as the 16th century Leonardo da Vinci (1452 – 
1519) in notes that appeared posthumously in 1540 for his 
Treatise on Painting (published in 1641) clearly anticipated the 
standards for the scientific method which were widely embraced 
a century later in rejecting thought experiments that fail the test 
of experience. By the 1660s, the scientific method, following the 
seminal contributions of Bacon, Galileo, Huygens and Boyle, had 
been clearly articulated by associations such as the Academia del 
Cimento in Florence (1657) and the Royal Society in England 
(founded 1660; Royal Charter 1662) with their respective mottos 
Provando e Riprovando (prove and again prove) and nullius in 
verba (take no man’s word for it)14.  
By the early 20th century standards for empirical assessment 
were put on a sound methodological basis by Popper (Sir Karl 
Popper 1902-1994) in his advocacy of a process of ‘conjecture 
and refutation 15 16 .  Hypotheses or claims must be capable of 
falsification; indeed, they should be framed in such a way that 
makes falsification likely. Life becomes more interesting if claims 
are falsified because this forces us to reconsider our models and 
the assumptions built into those models. This leads, then, to the 
obvious point that claims or models should not be judged on the 
realism or reasonableness of assumptions or on whether the 
model ‘represents’ for a public advocacy research group such as 
ICER their perception of a future, yet unknown, reality.  
Although Popper’s view on what demarcates science (e.g., 
natural selection) from pseudoscience (e.g., intelligent design) is 
now seen an oversimplification involving more than just the 
criteria of falsification, the demarcation problem remains 17.  
Certainly, there are different ways of doing science but what all 
scientific inquiry has in common is the ‘construction of 
empirically verifiable theories and hypotheses’. Empirical 
testability is ‘one major characteristic distinguishing science 
from pseudoscience’; theories must be tested against data. 
Indeed, paradoxically, while the development of pharmaceutical 
products and the evidence standards required by the Food and 
Drug Administration (FDA) for product evaluation and marketing 
approval is driven by adherence to the scientific method, once a 
product is launched and claims made for cost-effectiveness and, 
in the case of ICER, pricing and access recommendations, the 
scientific method is put to one side.  Pseudoscience succeeds 
science. 
The rejection of a research program that meets the standards of 
normal science by groups such as ICER is best exemplified by the 
latest version of the Canadian health technology guidelines 
where it is stated: Economic evaluations are designed to inform 
decisions. As such they are distinct from conventional research 
activities, which are designed to test hypotheses 18. While this 
position puts modeled health technology assessment in the 
category of pseudoscience, it is also what may be described as a 
relativist position. Rather than subscribing to the position that 
the standards of normal science are the only standards to apply 
in health care decisions and value claims, the relativist believes 
that all perspectives are equally valid. Health care decisions are 
to be understood sociologically. No one body of evidence is 
superior to another. Results of a lifetime modeled simulation are 
on an equal basis with those of a pivotal Phase 3 randomized 
clinical trial. For the relativist, the success of a scientific research 
program, in this case one built on hypothetical models and 
simulations, rests not on its ability to generate new knowledge 
but on its ability to mobilize the support of the community. 
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Basing decisions on models and simulations underpins the 
consensus view that evidence is constructed, never discovered. 
Instead of coming to grips with reality, science is about rhetoric, 
persuasion and authority 11. Truth is consensus. 
 
Models and Assumptions 
It is accepted that knowledge is provisional and permanently 
so. This stems from the obvious point that we can at no stage 
prove that what we ‘know’ is true. Attempting to believe or 
justify our belief in a theory is logically impossible. What we can 
do, by empirical assessment, is to try and demonstrate our 
preference for one theory over another (and apply it to the best 
of our knowledge).  
 
ICER’s response to public comments makes it clear that not only 
are the modeled value judgments driven by assumption but 
that there is considerable scope in the assumptions selected to 
‘drive’ alternative reference case lifetime models. The ICER 
model assumptions can be considered from three perspectives: 
(i) assumptions which derive from the clinical literature specific 
to the target therapies and (ii) general assumptions from the 
literature; and (iii) convenience assumptions that represent the 
ICER modeling perspective. In the first group we can point to 
trial end-points. Amarin in its stakeholder submission for the 
final draft evidence report notes that given the strong scientific 
evidence from REDUCE-IT, it is critical and appropriate to 
incorporate all statistically significant and clinically meaningful 
endpoint data for icosapent ethyl into the base-case Markov 
model to rigorously assess its economic value and budget 
impact 19 . ICER respondent by saying that, in its view it would 
focus on three endpoints in its base case MACE analysis and 
noting that this was an early decision made prior to the model 
analysis plan and that In many instances, the FDA’s decision 
around a trial’s primary endpoint may not be well aligned with 
the strongest evidence that informs lifetime costs and QALYs. It 
is not clear what ICER means by ‘strongest evidence’ if this is to 
support lifetime (i.e., unknown but by assumption) costs and 
measures of HRQoL. A further issue is the extent to which the 
hypothetical ICER target CVD population is consistent with the 
target populations defined by RCT protocols. Janssen makes the 
point, in the budget impact analysis, that prevalence estimates 
used by ICER for its product are grossly overestimated. ICER 
responds that: We are estimating patients under the approved 
label, not based on the eligibility criteria for COMPASS.  
 
In the second group, assumptions from the literature, Amarin 
again notes that ICER relies upon somewhat dated CVD cost 
data to drive its assumptions. ICER responds: We agree that 
there may be higher quality evidence sources for certain model 
inputs or that could be used to relax some of the model 
assumptions (emphasis added). However, the scope of this 
model exercise does not include detailed patient-level evidence 
generation in the eight-month review timeline. The exercise 
involves the team identifying best-available evidence sources. 
Therefore, to provide actionable critiques of this review process 
would involve suggesting alternative available evidence sources 
that are considered to be of the same or higher level of quality. 
In other words, we use what is available, even though the 
evidence source to justify an assumption may not be of high 
quality. 
 
In the third group are assumptions about future costs and 
prices. As ICER notes in its response to a further Janssen 
comment on ICER’s assumption that the price of their product 
will remain steady (but not with an annual 3% price increase) 
that: Following standard health economic practice we assumed 
that the net price of rivaroxaban would remain the same over 
time, as we have no way to predict price increases or decreases 
in the future (emphasis added). This caveat does not, 
apparently, apply to other modeled lifetime assumptions. 
 
Constructing ersatz worlds which were never intended to 
generate potentially falsifiable outcomes cannot be defended 
by an appeal to the ‘truth’ (‘quality of the evidence source’) of 
their assumptions. If a health technology assessment claim is 
built upon a series of assumptions, a reasonable question is to 
ask what is the status of the various assumptions? Are they to 
be viewed as ‘reasonable or ‘realistic’ metrics for an unknown 
future reality?  Have they been selected from the literature 
because they seem appropriate? Are they the ‘best available’ 
from limited data? Unless there are agreed criteria for assessing 
the ‘quality’ of an assumption, we face potentially competing 
claims for the ‘quality’ of assumptions in competing models.  
 
More to the point, there a belief that the fact that the selected 
assumptions are based, where feasible, on an empirical study 
validates the choice of assumption. For example, if the model is 
intended to incorporate utilities that have been reported in one 
or two studies (usually as few as that) for progression and time 
spent in the stages of a disease, then there is an immediate 
methodological issue. To claim that an assumption is valid is to 
revisit Hume’s induction problem (David Hume 1711-1776): an 
appeal to facts to support a scientific statement. Unfortunately, 
as Hume pointed out, no number of singular observations can 
logically entail an unrestricted general statement. Certainly, 
there may be comfort in reporting that ‘so far’ the claim that all 
swans are white has not been contradicted (until that Qantas 
vacation in Western Australia) so that one fully expects the next 
swan to be white. But as Hume pointed out, this is a fact of 
psychology and does not entail any general statement. From a 
utility perspective, the fact that one hundred papers have 
agreed (within limited bounds) generic utilities from the same 
instrument for a target population in a disease state stage is 
immaterial. We cannot secure this assumption: it cannot be 
‘established by logical argument, since from the fact that all 
past futures have resembled past pasts, it does not follow that 
all future futures will resemble future pasts’ 20. Claims, for the 
relevance of a constructed imaginary world built on the 
assumption that the model elements have been validated by 
observation is simply nonsensical.  
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Despite ICER’s continued embrace, logical positivism is dead. It 
died some 80 years ago. All knowledge is provisional. Poppers 
contribution was to make clear that Hume’s problem with 
induction can be resolved. We cannot prove the truth of a 
theory, or justify our belief in a theory or attendant 
assumptions, since this is to attempt the logically impossible. 
We can only justify our preference for a theory by continued 
evaluation and replication of claims. Constructing imaginary 
worlds, even if the justification is that they are ‘for information’ 
is, to use Bentham’s (Jeremy Bentham (1748-1832) memorable 
phrase ’nonsense on stilts’. If there is a belief, as subscribed to 
by ICER, in the relevance of constructing simulated worlds to 
drive formulary and pricing decisions, then it needs to be made 
clear that this is a belief that lacks scientific merit. 
 
Cardiovascular Disease: Which Generic QALY? 
Previous commentaries in this series have raised the concern 
that an unqualified use of the term QALY may give decision 
makers the impression that there is a common QALY standard 
that has been agreed to in health technology assessment 21. 
This is far from the truth. ICER uses the term, almost 
indiscriminately, without qualifying its claims that the utility 
metric driving the QALY estimate is based on an often arbitrary 
choice of measure. If the intent is to mandate a specific generic 
utility metric as is the case in the NICE reference case, then for 
US preference measures there are a number of options: EQ-5D-
3L, EQ-5D-5L, SF-36, SF-12, SF-6D. Confusion can arise when, as 
in the ATCD evidence report, ICER refers to the EQ-5D, without 
qualifying whether it is the 3-level or 5-level successor variant 
(introduced in 2009). Reviewing source documents referenced 
by ICER points to the 3-level variant. The EQ-5D-5L, introduced 
in 2009, is preferred given the floor and ceiling effects of the 
Eq-5D-3L and its lack of sensitivity. NICE in the UK is still 
struggling with the use of the 3- level as opposed to the 5-level. 
The current position is that the preferred measure is the EQ-5D-
3L. If data are collected using the EQ-5D-5L system, utility 
values in reference case analyses should be calculated my 
mapping the descriptive systems data to the 3L value 22. 
 
The point to note, however, is not just the limited number of 
responses open to patients within the health dimensions 
captured in the generic measure, but the limited ambit of those 
measures. Are these measures appropriate if the intent is to 
represent health related quality of life (HRQoL) in CVD? The EQ-
5D-3L, for example, is based on five broad health dimensions: 
mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Patients respond: no problems, some 
problems and major problems. The SF-6D, by contrast, has six 
health dimensions (with levels of response in parentheses): 
physical functioning (6), role limitations (4), social functioning 
(5), pain (6), mental health (5) and vitality (4).  
 
Without going into details of each of the various preference-
based multi-attribute health status systems it should be 
emphasized that the decision as to which generic measure to 
use either in a modeling exercise, a clinical trial or observational 
study does matter as the systems are far from identical. They 
differ in their coverage of health dimensions, in the defined 
levels, the description of these levels, the severity of the most 
severe level, the populations surveyed, the instruments used to 
determine the preference scoring and the theoretical approach 
for modeling the preference data into a scoring formula 23.  The 
same patients can have quite different scores depending on 
choice of instrument. This is seen even with the two versions of 
the EQ-5D. The EQ-5D-5L yields, at least in the case of 
rheumatoid arthritis where it is possible with data from the US 
National Data Bank for Rheumatic Diseases (NDB) to contrast it 
with the EQ-5D-3L for the same respondents 24. The EQ-5D-5L 
yielded higher utility scores and a tighter distribution of those 
scores, with consequent different claims for cost-effectiveness. 
This is attributable to the five rather than three response levels 
of the E!-5D-5L: no problems, slight problems, moderate 
problems, severe problems and extreme problems.  
 
Similar findings occur with the EQ-5D-5L and EQ-5D-3L when 
econometric modelling is used to apply mapping algorithms to 
transition either between the two versions of the EQ-5D as well 
as mapping to health state utilities from non-preference bases 
outcomes measures (e.g., HAQ-DI scores in RA). Although there 
are now good practice guidelines developed by the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) for those undertaking mapping studies, the 
fact remains that different mapping algorithms can produce 
different utility values with the analyst hopefully defending 
their choice of method 25. Although NICE, as noted, has been 
attempting to transition from the EQ-5D-3L to the EQ-5D-5L 
over the past few years it faces significant challenges, not only 
in developing a value score, but because the switch has been 
demonstrated to lead to substantially different estimates of 
incremental QALYs and claims for cost-effectiveness. This has 
been shown using both the NDB and the EuroQoL Group data 
sets 26.  
 
ICER has used both utility values gleaned from selected studies 
where the study has either presented utility values captured 
directly from target patient populations or utility values 
captured indirectly from clinical markers. What does not seem 
to have been appreciated is the implications for ICER value 
judgements of options open in: (i) choice of generic utility 
instrument; (ii) choice of mapping; and (iii) the application of 
willingness to pay thresholds to support ICER recommendations 
for possible price discounting and/or access to care under its 
affordability alerts. 
 
In respect of point (iii) above, it should be made clear that any 
value judgement (e.g., for price discounting) based upon a 
willingness to pay threshold (e.g., $50,000 per incremental 
QALY) is only meaningful if the technique(s) used to generate 
utility values as inputs to QALY estimates, ceteris paribus, are 
specified.  As utility values are discretionary, defined by the 
generic instrument and the techniques applied to map to that 
instrument, a cost per QALY claim will not only be specific to the 
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characteristics of the target patient population in a disease 
state for the products selected, but to the construction or 
choice of utility metric. A mandatory or fixed willingness to pay 
threshold for incremental QALYs will yield different 
recommendations by ICER for possible price discounting 
depending on the value metric as the incremental QALY count 
will differ. Not only are the ICER models imaginary constructs, 
yielding different recommendations depending upon the 
choice of assumption, but the utility value algorithm is 
discretionary. There is no standard QALY or standard mapping 
algorithm to support across the board application of fixed 
willingness to pay thresholds. ICER should create different 
willingness to pay thresholds for the various utility metrics if its 
claims for price discounting are to be consistent across the 
various therapies reviewed. As an example, consider an 
incremental cost-per-QALY where the incremental costs are 
fixed but the incremental QALY count is different. One generic 
instrument may yield 5 lifetime incremental QALYs while 
another yields 10 incremental QALYS. If incremental costs are 
$500,000 (over the hypothetic average patient lifetime), the 
first model will yield an incremental cost per QALY of $50,000, 
the latter $100,000. If the willingness to pay threshold in 
$50,000, the second model will lead to an ICER 
recommendation for price discounting while the first model 
results in a no change recommendation. If ICER is to be 
consistent in its recommendations then the $50,000 willingness 
to pay threshold cannot be applied to both.   
 
A failure to appreciate the impact of alternative utility metrics 
on value judgements is seen in the ACC/AHA statement on cost 
and value methodology 27. As part of the value assessment for 
the quality of evidence in health economic studies they 
recommend integrating a ‘Level of Value’ into clinical guideline 
recommendations. The levels are defined in terms of cost per 
QALY gained (e.g., high value an ICER < $50,000 per QALY 
gained). No account is taken of the choice of utility metric and 
its potential impact on value level. 
 
Similar concerns are raised in respect of the application of the 
CVD PREDICT microsimulation model 28 . This model, which was 
developed to the comparative and cost-effectiveness of CVD 
policies has been applied in an assessment of financial 
incentives and disincentives for food purchases under the US 
Supplemental Nutrition Assistance Program (SNAP)29. The 
evaluation included estimates of QALYs gained and costs per 
QALY under various SNAP policy scenarios for timelines of 5, 10, 
20 and the lifetime of participants. Unfortunately, the authors 
failed to indicate which utility metric was used to generate 
QALY estimates. A more recent microsimulation of the 
economic impact of incentivizing diet with CVD PREDICT in 
Medicare and Medicaid recipients raised the same issues 30 .    
 
It is absurd for ICER to claim, as it does in its recent draft 
evidence report for Oral Semaglutide for Type 2 Diabetes, 
where it cobbles together utility values from the HUIMk3 with 
mapped EQ-5D-3L metrics that:   The utility values for events 
modeled from the risk equations were drawn from two sources 
due to a lack of a single comprehensive source of health-related 
quality of life inputs. It is also important to point out that the 
two sources used different preference-weighted measures (EQ-
5D and HUI3), and these two instruments are known to produce 
slightly different utility estimates (emphasis added; pg. 73) 31. It 
is unclear what is meant by ‘slightly different’ as no references 
are given for a direct comparison of the two utility value scores 
for identical patients in the Type 2 diabetes target patient 
group. We might as well say, as ICER would no doubt endorse, 
that it is immaterial as far as ICER is concerned whether it uses 
for its in-house modeling the EQ-5D-3L or EQ-5D-5L utility 
values in its modeling for the same evidence report as the two 
yield only ‘slightly different’ estimates even though the 
evidence to date would suggest this is patently false. If ICER is 
to appoint itself as the sole arbiter in point position as the go-
to health technology assessment agency then it needs to set 
standards for its imaginary reference case modeling that have 
at least minimum credibility. As it stands a company such as 
Novo Nordisk, the manufacturer of Oral Semaglutide should 
make it quite clear that any ICER modeled claims should be 
rejected out of hand. 
 
It is worth also pointing out that utility values captured in the in 
the ACTD ICER model are taken from publicly available 
literature with modifications introduced by the model builders. 
The scores were primarily from a chronic disease study that 
provided nationally representative EQ-5D-3L scores for a range 
of chronic conditions defined by ICD9 codes32. Disutility scores 
were applied to modeled MI, stroke, severe atrial fibrillation, 
major bleeding and acute non-fatal major adverse limb events 
(Table 4.7).  In the case of stroke, as the severity can vary, a 
weighted average stroke utility was computed (Table E5) from 
utility estimates stratified by dependency level from the Virtual 
International Stroke Trials Archive (VISTA)33.  
 
Unfortunately, ICER does not explain, in the ACTD model, its 
reasons for the choice of utility metric, or the criteria it applies 
in that selection. Apart from the possibility that it was all they 
could find, why did they choose the EQ-5D-3L instrument? In 
this respect it is of interest to note ICER’s response to an 
observation by the National Forum for Heart Disease And 
Stroke Prevention that:  We continue to view QALY as an 
imperfect metric because it has potential for discrimination 
against those with baseline disabilities comorbidities and 
advanced age, all of which are common in CAD patients. The 
response from ICER is somewhat disingenuous:  The QALY is the 
gold standard for measuring how medical treatment improves 
and lengthens patients’ lives, and therefore has served as a 
fundamental component of cost-effectiveness analysis in the US 
and around the world for more than 30 years. Because the QALY 
records the degree to which a treatment improves patients’ 
lives, treatments for people with serious disability or illness have 
the greatest opportunity to demonstrate more QALYs gained 
and justify higher prices. Two  questions may be raised: (i) why 
has a particular QALY system been selected and (ii) the 
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possibility that utility metrics for functional status and symptom 
change may have nothing to do with how patients, rather than 
treating physicians, view the benefits from therapy in meeting 
their needs. 
 
Ordinal versus Cardinal Measures 
Discussions over the application of utility metrics may seem 
surreal (if not irrelevant) once we consider the measurement 
properties of the EQ-5D-3L and other preference-based multi-
attribute systems. While future commentaries will address the 
question of measurement in health technology assessment in 
more detail, it is sufficient for our purposes to point out that 
these instruments generate raw scores, captured as ordinal 
scales, rather than interval or cardinal calibrations 34 35. In the 
case of ordinal scales while intervals (e.g., based on utility raw 
scores and increments within a scale of 0 – 1) are assumed to 
be equal, the intervals are, by definition, unknown. If attempts 
are made to manipulate the scores mathematically (e.g., 
estimating means and standard deviations, estimating change 
scores or effect sizes) the results are not logically valid  36.  
 
The fact that utility metrics are typically expressed through 
ordinal scales rather than attempting through Rasch modeling 
to translate the ordinal to a cardinal or interval scale means that 
conclusions based on these metrics should be put to one side. 
The ICER QALY is not defensible on purely measurement 
grounds. The Rasch model, if its standards are met, means that 
the cardinal translation complies with the two axioms of 
measurement theory: invariance of comparison within the 
scale and sufficiency in the total score 36.  Although Rasch 
Measurement Theory (RMT) has been widely used in the last 60 
years in education and psychology to achieve coherent 
unidimensional scores to capture latent constructs, it has yet to 
gain a firm acceptance in health technology assessment. In 
consequence, groups such as ICER, following the notional ISPOR 
standard for ‘state of the art’ modeling for value claims,  
continue to produce evidence reports where recommendations 
for price discounting and affordability fail to meet required 
fundamental measurement axioms 37. The application of 
threshold willingness to pay criteria founders because the 
reference case incremental cost-per-QALY estimates have no 
logical basis.   
 
ICER Disclaimers 
It would have been more informative for ICER to have pointed 
out: 
 
 That the use of the EQ-5D (or other multi-attribute 
measure) has ordinal measurement rather than RMT 
cardinal calibration 
 Mathematical manipulations (e.g., means, standard 
deviations) to create utility stage of disease lifetime 
profiles and QALYS are not logically valid 
 
and, for those who are committed to ordinal measurement: 
 
 There is no agreed QALY gold standard or universally 
accepted single utility scoring algorithm, rather there 
are both generic and disease specific instruments that 
claim to capture the relevant dimensions of quality of 
life (or, more accurately, health related quality of life) 
both across disease states and for CVD as a target 
disease state 
 Although not mentioned in the evidence report (you 
would have to check the references) it should have 
been pointed out that the utility metric used by ICER 
in this report (it differs by ICER report) is the EQ-5D-3L 
measure, which is only one of a number of generic 
utility metrics and that can yield different values 
within disease states for defined target populations. 
Hence, when combined with modeled time estimated 
as being spent in a disease stage, which will depend on 
the model and its assumptions, different utility 
algorithms will give different QALY estimates 
 Certainly, QALYs have been a fundamental component 
of cost-effectiveness studies although the majority are 
constructed models which can yield, even in the same 
disease state, different claims for cost-effectiveness 
given different model structures, assumptions and 
choice of utility metric (which also raise the question 
whether the term ‘cost-effective’ is meaningful) 
 To be totally transparent, ICER should have reviewed 
the various utility metrics and HRQoL outcomes for 
CVD with both generic and disease specific 
instruments and defended their choice of the EQ-5D-
3L option 
 ICER should also have detailed the health dimensions 
and levels captured by the EQ-5D-3L and made the 
case that this instrument, in contrast to others, (i) 
captures the most important and relevant health 
dimensions for CVD experience in the target patient 
population and (ii) is appropriate to the impact of the 
two therapies considered for change over time as CVD 
progresses and adverse events occur 
 ICER should have demonstrated, from its literature 
review, the QALY change (or just the utility metric 
change) for the application of the EQ-5D-3L is 
considered clinically meaningful in the target CVD 
population 
 ICER might also have noted that there is a ‘successor’ 
utility metric, the EQ-5D-5L and pointed out that the 
metrics reported (particularly if they have been 
captured for the target CVD population) may differ 
between these two versions of an instrument with the 
same health dimensions (but different response 
levels) 
 ICER might  have pointed out that in a lifetime 
reference case model, claims for utility metrics are by 
assumption, with possible interpolations from ’expert 
opinion’ or their own modelers, and that there is no 
way the claimed metrics and overall QALY estimates 
can be ever be evaluated as empirical value claims 
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 If the concern is with evidence based value claims, 
rather than simulated value judgements, ICER might 
point out that if the protocols for the pivotal CVD trials 
had included the EQ-5D-3L as a primary/secondary 
endpoint then the outcomes reported may have been 
different from those assumed by ICER in its modeling 
from third party sources 
 Last but not least, the impression given that any 
concerns with QALYs have long been settled is false: 
there is an ongoing debate over the theoretical basis 
for preference-based utilities, the application of 
weighting and scoring algorithms, the application of 
generic utility instruments in older populations and 
rare diseases, the role of caregivers   and the relevance 
of generic utility measures in target disease states  
such as CVD 38 39. 
 
It is understandable that ICER’s views on QALYs should be 
positive (and defensive), after all lifetime reference case based 
value judgments are an integral, if not the central, element of 
their business model. Unfortunately, adherence to this meme 
puts ICER in a straightjacket. If the reference case is abandoned 
or if ICER ‘relents’ and allows non-generic utility measures as 
part of its imaginary modeling, then it opens the door to even 
more competing imaginary worlds.  
 
Even so, the question remains unanswered: what are the 
characteristics of the EQ-5D-3L instrument that make it 
appropriate for assessing health status in CVD? It would be a 
mistake to describe the ICER model in ‘capturing’ a generic 
utility metric with resultant QALY claims, as indicative of the 
quality of life of patients in the target patient group. Far from 
it; at best, unless ICER can demonstrate otherwise, the QALY 
claim reflects the responses of patients to the health 
dimensions captured in the generic measure together with the 
choice of levels reported within each dimension. ICER is 
assuming that these health dimensions are the most relevant in 
CVD.  ICER fails to point out that the last decade has seen a 
robust and extended debate over the relevance of the narrow 
generic measures of value in economic evaluations 40. 
As a general representation of health status, instruments such 
as the EQ-5D may be appropriate in national health surveys to 
give a ‘broad brush’ picture of current health status, it is 
another issue entirely to consider them as appropriate in target 
disease states. 
 
Of course, if the ICER reference case means that ICER is 
committed to the use of generic HRQoL measures as the metric 
for QALY claims then it should be made clear that ICER has no 
intention of modifying its modeling to accommodate disease 
specific measure. Irrespective of whether or not these might be 
preference based and meet required psychometric and FDA 
audit standards, let alone required measurement properties, 
ICER will not include them. Patient advocates might point out 
that these generic measures are not designed to capture HRQoL 
or QoL specific to CVD or other target populations in disease 
state, but their protests will be ignored. 
 
Disease Specific Instruments 
If ICER is concerned about justifying its application, from third 
party sources, of a generic instrument such as the EQ-5D-3L in 
CVD, it might take as reference points two widely used HRQoL 
measures: the MacNew and HeartQoL instruments. Without 
endorsing the relevance of lifetime simulated models to 
support non-evaluable value judgement claims, it would be 
instructive if ICER compared the health dimensions of the EQ-
5D-3L with both of these instruments.  
 
The MacNew instrument was designed to evaluate how daily 
activities and physical, emotional and social functioning are 
impacted by persons with coronary heart disease 41. It consists 
of 27 items in three domains: physical limitations (13-items), 
emotional functioning (14 items) and social functioning (13 
items). In addition, there are 5 items that capture symptoms: 
angina/chest pain, shortness of breath, fatigue and dizziness. 
The questions refer to the previous 2 weeks, with a low 
respondent burden (10 mins). It is now in 25 language versions.  
 
The HeartQoL questionnaire is a hybrid developed from the 
MacNew and two condition specific questionnaires measuring 
HRQoL in patients with ischemic heart disease. The instrument 
comprises 14 items, 10 capturing physical status and 4 items for 
emotional well-being, together with summary scores. A 
comparison test-retest of the two instruments pointed to their 
comparability with the focus on the HRQoL as a ‘core’ 
instrument 42. The HeartQoL, together with the MacNew, has 
been validated in   patients with angina, myocardial infarction, 
and heart failure. The HeartQoL was developed to be a single, 
reliable and valid core HRQoL instrument for patients with 
chronic heart disease for between diagnosis comparisons and 
changes in HRQoL following interventions 43 44 45.   
 
The Patient Voice 
A further issue that should be noted is whether or not HRQoL 
instruments, such as the HeartQoL actually capture a latent QoL 
construct for patients with CVD. Since the mid-1990s there has 
been a debate in health technology assessment on the concept 
of patient value and whether HRQoL instruments, which focus 
on clinical functioning and symptoms, reflect the patient voice: 
the extent to which competing therapies meet patient needs. 
Value is hypothesized, within the needs model, to be dependent 
on the extent to which human needs are fulfilled 46. In this value 
framework, the presence of disease and its treatment are 
considered major influences on needs fulfillment. Certainly, 
HRQoL disease specific measures may capture clinical 
manifestations of disease. We may infer, indirectly, that this 
may go some way towards needs fulfillment. This is not 
sufficient. We require an instrument that is patient centric (and 
not just an outcomes measure) and one that provides a cardinal 
measure, a unidimensional scale, of needs fulfilment 46. 
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There are, in fact, over 30 patient centric, needs fulfillment 
measures, that have been developed and applied 47. The focus 
of these instruments is to provide a rating scale that is assumed 
to measure directly a common QoL latent construct. If it can be 
demonstrated that they meet the standards for Rasch 
Measurement Theory (RMT), the successor to Classical Test 
Theory (CTT), then the instrument can be assumed to measure 
the underlying construct with the final selection of response 
items generating a technically valid unidimensional scale with a 
single score. This is not a profile instrument; rather it is an index 
to support claims that needs are potentially fulfilled 47. As 
disease-specific needs measures, with items generated directly 
from qualitative interviews with target patient populations, are 
developed to the same RMT standard, they can support direct 
comparisons between diseases. As McKenna et al conclude: (i) 
most available patient reported outcomes measures fail to 
employ a meaningful construct theory to guide their 
development and, consequently cannot be validated and (ii) 
employ CTT rather than a response model … (so that) it is not 
possible to relate scores on the scales to a construct theory 35. 
 
Exeunt ICER QALYs? 
If our concern is with developing claims that are credible, 
evaluable and replicable, rather continuing to subscribe to 
pseudoscience in the construction of ersatz worlds, then the 
continuing role of QALYS in health system decision making is 
problematic. While we might argue for the information role of 
ersatz claims, should we continue with those claims if we know 
(but ignore) the failure of ordinal utility scores to meet interval 
scaling standards? A more cynical position might be to argue 
that QALYs are only seen as relevant in decision making because 
lifetime ersatz worlds rely on generic ordinal utilities, applied 
by stage of disease, to create simulated lifetime QALY counts. 
This is not only a necessary measure of value but the only one 
applicable if value propositions are driven by matching 
incremental cost per QALY estimates to willingness to pay 
thresholds. Take away utilities on measurement grounds, then 
the QALY edifice and claims for incremental cost per QALY 
differences collapses, together with the notion that ersatz 
worlds have a meaningful role.  To complete the demolition, we 
might then bring in the need for measures of value that 
represent the patient voice not the views of physicians on 
therapy benefits.  
 
The earlier QALY commentary, by the present author, following 
a review of the practical impact of modeled cost-per-QALY 
claims and the unlikely event that they would ever be followed 
up as credible and evaluable hypotheses, concluded that: In 
retrospect, it is doubtful, that the great expectations for QALYs 
could ever be realized outside of reference case imaginary 
worlds, or the willingness of decision makers to suspend belief 
in the standards of normal science, and accept lifetime cost-per-
QALY claims as decision criteria. Unless, therefore, a case can be 
made for short-term and evaluable QALY claims, there seems 
little scope for QALYS, and associated cost-per-QALY claims, as 
inputs to formulary decision making. Perhaps, as Pip says to 
Estella, it has been ‘a vain hope and an idle pursuit’ 48. After over 
30 years perhaps we can put QALYs to one side and return to 
clinically and quality specific endpoints  in comparative claims 
for pharmaceutical products in disease and therapeutic areas 7 
. The qualification to add here is to recognize the importance of 
fundamental measurement and the needs of the patient if we 
move to more relevant and evaluable benefit claims. 
 
Product Affordability and Budget Impact Thresholds 
Although a therapy may meet ICER’s arbitrary willingness to pay 
thresholds for cost-effectiveness as determined by the 
imaginary modeled construct and the choice of utility metric 
matched to the appropriate willingness to pay threshold, this 
first hurdle may be surmounted only to be halted at the second 
hurdle: ICER’s potential budget impact threshold. 
 
In May 2019 ICER determined that the annual budget impact 
threshold for each individual new molecular entity would be 
$819 million. If projected annual US spending on a specific drug 
exceeds this threshold then ICER will determine the maximum 
number of eligible patients who would be able to receive the 
therapy, at multiple possible pricing points (lower than the 
price deemed cost effective in the first hurdle analysis) without 
exceeding the threshold. In effect, the ICER proposal is for a 
central planning rationing regime with recommendations for 
patient access, presumably through some form of prior 
authorization, irrespective of the benefits that excluded 
patients might receive. 
 
How is this molecular ceiling created?  ICER calculates an 
estimated annual threshold for all net health care cost growth 
for all drugs and divides this by an estimate of FDA new 
molecular entity approvals. This yields an average annual 
threshold for average cost growth per individual new molecular 
entity (current estimate $409.6 million). This is then doubled to 
give the $819 million threshold for individual new molecular 
entities that ICER has arbitrarily decided separate the 
affordable from the non-affordable.  
 
Whether anyone should take this back-of-the-envelope 
rationing alert seriously is a moot point. In the case of both 
rivaroxaban and icosapent ethyl, ICER issued what it describes 
as an Access and Affordability Alert. Apparently, the ICER 
convened group of experts at the final meeting on the draft 
evidence, stated that they would consider using rivaroxaban in 
30% or more of eligible patients while, according to ICER;’s 
affordability projections, only 6% of patients in the US could be 
treated in a given year before crossing the threshold of $819 
million. Similarly, while ICER’s clinical experts at the meeting 
stated they believed the majority of eligible patients would 
want to be on icosapent ethyl, only 4% of eligible patients could 
be treated before breeching the budget threshold. 
 
To recommend a ceiling for patient access to meet a notional 
budget threshold is to put to one side assessed clinical benefits 
for the individual patient, and whether this merits additional 
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funds being allocated, as well as potentially creating waiting 
lists for access. It is all well and good to recommend prior 
authorization but without recommended criteria for 
approval/refusal, it is a hollow recommendation. After all, it 
would be presumably possible to translate the aggregate 
budget limit into QALYs and estimate the allocation of QALYs to 
each molecular entity and estimate the number of patients 
allowed to utilize the therapy! Unfortunately, this would raise 
the question again of why generic ordinal QALYs are used when 
the focus is presumably (again) of the benefits and harms to 
patients. ICER would also have to argue that, if the object from 
a societal perspective is to maximize health benefits then it 
would be reasonable for ICER to nominate other products in 
specific disease areas that could either be dropped from 
formulary or have price reductions so that resources could be 
shifted to ‘high value’ therapies. This, of course, is unlikely but 
the first step would be to agree a utility metric that is 
standardized across disease states to populate imaginary ICER 
cost-per-QALY worlds and which met fundamental 
measurement standards. 
 
Conclusions:  The Patient Perspective 
If we are to understand the contribution of additive therapies 
in cardiovascular disease in  real world treating environments, 
through for example protocol driven observational studies, 
then the focus should be on those attributes of a target disease 
state, defined for a target population, that attempt to build 
upon claims from RCTs and reflect the patient voice. Typically, 
RCTs are of short duration and while it is possible to track 
patients adherence patterns with some clinical markers from 
laboratory tests, the ability to track patient centric outcomes in 
a needs-fulfillment measure would seem a key contribution. Of 
course, if ICER announced that it would only develop models 
where the EQ-5D-5L was the mandated value metric then it 
would not only have to revisit all previous reports and provide 
revised recommendations for pricing and access, but admit that 
this would do nothing to alleviate concerns with the application 
of ordinal measures to support recommendations for pricing 
and access. It would be of interest to speculate on the legal 
implications of this for pricing and access decisions imposed on 
manufacturers by decisions of health systems based on ICER 
models. 
 
If contributing to our knowledge of therapy response in CVD is 
an objective, then the ICER reference case simulation with 
constructed value judgements adds nothing. Indeed, it may 
have a negative impact.  A similar conclusion holds in respect of 
the CVD PREDICT microsimulation package should ICER decide 
to assess its outcomes vis à vis regression modeling in a Markov 
framework. Indeed, ICER value judgements may have the effect 
of limiting access to therapy where formulary committees take 
the ICER value judgements at face value without appreciating 
the pseudoscientific nature of the simulation that is driving 
those claims both for cost-effectiveness and affordability.  
 
Next Steps 
In CVD disease we should be looking, not to ersatz 
pseudoscientific constructs, but to a program focused on 
patient response and patient needs that goes beyond RCTs to 
provide input for therapy decisions and the tracking of patients. 
This perspective is not, of course new. We have ample 
experience with building patient registries and of building on 
existing patient registries to capture the potential of novel 
therapies. We also have experience in extrapolating from RCTs 
and building short term models that can be evaluated and the 
results reported back to formulary committees in a meaningful 
time frame. At the same time, there are a range of data bases 
to support ‘data mining’. Rather than constructing imaginary 
worlds to support hypothetical value judgements for pricing 
and access, ICER would be better employed developing models 
that actually add to our knowledge of the impact of additive 
cardiovascular therapies to support formulary decisions and 
treatment guidelines, notably measures of patient benefit that 
meet RMT standards.  
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